AAVantgarde's Professor Auricchio Achieves New Milestone
MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to the field of gene therapy.
A Prestigious Appointment in Gene Therapy
The European Society of Gene and Cell Therapy (ESGCT), which is composed of talented researchers and clinicians from across Europe, celebrated Professor Auricchio's election during their Annual General Meeting. This recognition reflects the hard work and dedication he has demonstrated throughout his career, making an impact on the future of gene therapy.
Influence and Achievements
With over 140 peer-reviewed publications and a plethora of patents attributed to his name, Professor Auricchio's work has been recognized internationally. As the Scientific Director of TIGEM and a Professor of Medical Genetics at the University "Federico II" in Naples, Italy, his multifaceted roles contribute significantly to advancing the gene therapy landscape.
A Recognition of Dedication
Dr. Natalia Misciattelli, the CEO of AAVantgarde, expressed her congratulations, emphasizing the importance of this recognition. She stated, "Congratulations to Alberto on this important and well-deserved recognition of his outstanding scientific contributions to the field of gene therapy. We are privileged and honoured to work with him as Founder and Chief Scientific Officer of AAVantgarde." This sentiment underscores the pride and respect held for Professor Auricchio within the company.
About AAVantgarde Bio
AAVantgarde Bio is a pioneering biotechnology firm operating on an international level. The company is at the forefront of developing proprietary Adeno-Associated Viral (AAV) vector platforms, specifically designed to overcome the gene delivery limitations characterized by traditional AAV vectors. Their innovative platforms show promise in delivering large genes effectively to both ocular and non-ocular tissues.
Current Research Focus
Currently, AAVantgarde is validating its leading programs in the context of inherited retinal diseases, addressing critical unmet needs in this area. Their primary focus is on Usher syndrome type 1B, which has advanced into clinical trials, marking a significant step in their mission to provide effective solutions in gene therapy.
Connecting with the Company
AAVantgarde continues to grow and innovate, driven by a vision to change lives through gene therapy. For any inquiries or further information about their groundbreaking work, reach out to Dr. Magda Blanco, Head of Corporate Development at AAVantgarde, via email at info@aavantgarde.com. This level of accessibility reinforces their commitment to transparency and public engagement.
Frequently Asked Questions
What is the significance of Professor Auricchio's election?
The election of Professor Auricchio as President of the ESGCT highlights his outstanding contributions and leadership in the field of gene therapy.
What does AAVantgarde Bio focus on?
AAVantgarde Bio focuses on developing advanced AAV vector platforms for large gene delivery and aims to address unmet needs in gene therapy.
Where is AAVantgarde based?
AAVantgarde Bio is an international biotechnology company based in Italy.
What is the lead program for AAVantgarde?
The lead program for AAVantgarde is in Usher syndrome type 1B, which is currently in clinical stages.
How can I contact AAVantgarde for more information?
You can contact Dr. Magda Blanco at info@aavantgarde.com for inquiries regarding AAVantgarde and their projects.
